Tag Archives: hemodialysis

Constipation and Hemodialysis, Increased Risk of Cardiovascular Events and Mortality

Is Constipation Just a Minor Digestive Issue?

Constipation and Hemodialysis, Constipation is often considered a minor digestive issue, but recent research suggests it can have serious health implications. In particular, for patients undergoing hemodialysis due to chronic kidney disease (CKD), constipation is associated with an increased risk of cardiovascular events and mortality.

A large-scale study in Korea revealed that 25.9% of hemodialysis patients suffer from constipation, and these patients face up to a 15% higher risk of cardiovascular events and death. Let’s explore the causes, consequences, and possible management strategies for constipation in dialysis patients.


📊 Study Overview: Investigating the Link Between Constipation and Cardiovascular Risk

This study utilized data from the Korean Health Insurance Review and Assessment Service (HIRA) in 2015, analyzing 35,230 hemodialysis patients to examine the correlation between constipation, cardiovascular disease, and mortality rates.

Study Design and Key Parameters:

  • Participants: 35,230 CKD patients undergoing hemodialysis
  • Definition of Constipation: Patients who were prescribed laxatives 180 times or more within a year
  • Outcome Measures:
    • Primary Outcomes:
      • Acute ischemic stroke
      • Hemorrhagic stroke
      • Myocardial infarction
      • All-cause mortality
    • Secondary Outcomes: Individual analysis of each component of the primary outcomes

📈 Study Results: Increased Cardiovascular Risk in Constipated Patients

🔹 Prevalence of Constipation in Hemodialysis Patients

According to the study, 25.9% (9,133 patients) of hemodialysis patients suffered from constipation.

🔎 Why is Constipation More Common in Dialysis Patients?
Dietary Restrictions: Limited potassium and phosphorus intake reduces fiber consumption
Fluid Restriction: Dialysis patients must limit fluid intake, leading to harder stools
Medication Side Effects: Potassium binders, phosphate binders, and iron supplements contribute to constipation
Reduced Physical Activity: Dialysis patients often have limited movement, slowing digestion

🔹 Characteristics of Constipated Patients

Patients with constipation were older and had a higher prevalence of diabetes, hypertension, and ischemic heart disease compared to those without constipation.

Characteristic No Constipation (n=26,097) Constipation (n=9,133)
Average Age (years) 58.8 63.7
Diabetes (%) 56.6% 72.6%
Hypertension (%) 82.9% 87.9%
Ischemic Heart Disease (%) 31.0% 40.1%
Body Mass Index (BMI) 22.3 22.6

🔎 Interpretation: Patients with constipation tend to have higher metabolic and cardiovascular risk factors, potentially exacerbating health issues.

🔹 Association Between Constipation, Cardiovascular Events, and Mortality

🔍 Key Findings After 5.4 Years of Follow-Up:
Constipated patients had a 15% higher risk of cardiovascular events
16% increased risk of ischemic stroke
14% higher risk of all-cause mortality
No significant association with hemorrhagic stroke or myocardial infarction

🔽 Adjusted Hazard Ratios for Cardiovascular Risk

Outcome Model 1 (Basic Adjustments) Model 2 (Additional Adjustments) Model 3 (Fully Adjusted)
Total Cardiovascular Events 1.24 (1.20-1.29) 1.22 (1.17-1.26) 1.15 (1.11-1.20)
All-Cause Mortality 1.26 (1.21-1.31) 1.23 (1.18-1.28) 1.14 (1.10-1.20)
Ischemic Stroke 1.30 (1.15-1.47) 1.26 (1.11-1.42) 1.16 (1.02-1.32)

📢 In summary, constipation significantly increases the risk of cardiovascular disease and mortality in dialysis patients.


🧐 Why Does Constipation Increase Cardiovascular Risk?

1️⃣ Gut Microbiota Imbalance (Dysbiosis)

  • Constipation disrupts gut microbiota, reducing beneficial bacteria and increasing inflammation.
  • Altered gut microbiota is linked to cardiovascular diseases and metabolic disorders.
  • Study: Wang et al. (2011) found increased TMAO (Trimethylamine N-oxide) levels in constipated patients, a compound known to raise heart disease risk.

2️⃣ Sudden Blood Pressure Spikes (Valsalva Maneuver)

  • Straining during bowel movements can cause a sudden increase in blood pressure, potentially triggering strokes or heart attacks.
  • Study: Ishiyama et al. (2019) found a direct correlation between constipation-induced blood pressure spikes and cardiovascular events.

3️⃣ Nutritional Deficiencies & Metabolic Dysfunction

  • Low fiber intake and chronic constipation can lead to nutritional imbalances.
  • Study: Sumida et al. (2019) found that CKD patients with constipation had a higher prevalence of metabolic disorders and cardiovascular risk factors.

📢 Conclusion and Recommendations

Constipation is not just a digestive problem—it significantly increases cardiovascular and mortality risks in hemodialysis patients.
Proper dietary adjustments, lifestyle modifications, and medical interventions are essential to prevent complications.
Further studies are needed to determine whether treating constipation can improve survival rates in dialysis patients.


🔗 Reference

  • Park SC, Jung J, Kwon YE, et al. Constipation and risk of death and cardiovascular events in patients on hemodialysis. Kidney Res Clin Pract 2025;44(1):155-163. DOI: 10.23876/j.krcp.24.174

Bridging CKD treatment gap : Real Solutions

apixaban

Apixaban for hemodialysis: A Promising Solution

Apixaban for hemodialysis, For patients undergoing hemodialysis, maintaining vascular access patency is crucial for effective treatment. However, blood clots often form in arteriovenous fistulas (AVF) and arteriovenous grafts (AVG), leading to frequent interventions and increased healthcare costs.

A recent study published in Kidney International sheds light on Apixaban, an anticoagulant that has shown promising results in preventing recurrent thrombosis in dialysis patients. This article explores its effectiveness, safety, and key considerations for use.


What is Apixaban?

Apixaban is a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa, a key protein in blood clot formation. Compared to traditional anticoagulants like warfarin, Apixaban offers several advantages:

Lower risk of major bleeding
Predictable and consistent anticoagulation
No need for frequent blood monitoring
Less interference with dialysis and kidney function


Key Findings from the Study

A randomized controlled trial (RCT) was conducted on 186 hemodialysis patients to compare Apixaban + standard care vs. standard care alone over three months.

🔍 Study Results

📌 Reduced Thrombosis Recurrence

  • Apixaban group: 24.0% experienced thrombosis within 3 months
  • Control group: 40.8% experienced thrombosis within 3 months
  • Result: 52% lower risk of thrombosis recurrence in the Apixaban group

📌 Improved Vascular Access Patency

  • Apixaban helped maintain vascular access patency better than standard treatment alone
  • At three months, the Apixaban group showed 67.8% patency, compared to 50.5% in the control group

📌 Safety Profile

  • Major bleeding risks were similar between both groups
  • Minor bleeding (skin or mucosal bleeding) was slightly higher in the Apixaban group (22.6% vs. 7.5%)

What Hemodialysis Patients Should Know About Apixaban

1️⃣ Consult Your Nephrologist First

Not all patients are suitable for anticoagulation therapy. Discuss with your doctor whether Apixaban is appropriate for your condition.

2️⃣ Monitor for Bleeding Signs

While Apixaban reduces blood clot risk, it may increase minor bleeding. Watch for:
Frequent nosebleeds or gum bleeding
Blood in urine or stool
Unusual bruising that lasts long

3️⃣ Maintain a Healthy Lifestyle

Combining Apixaban with healthy habits can further reduce clot risk:
Low-sodium diet – Helps manage blood pressure and vascular health
Regular exercise – Improves circulation and overall well-being
Adequate hydration – Prevents blood thickening and clot formation


Is Apixaban the Right Choice for You?

Apixaban has proven benefits in reducing vascular access thrombosis while maintaining a relatively safe profile. Unlike warfarin, it does not require frequent monitoring and has a lower risk of severe bleeding.

However, not all dialysis patients may benefit from it, so medical consultation is essential before starting Apixaban therapy.


Conclusion: A Step Forward in Hemodialysis Care

Preventing vascular access thrombosis is critical for dialysis patients. Apixaban offers a potentially safer and more effective option to reduce clot recurrence and improve dialysis efficiency.

If you or a loved one is on hemodialysis, discussing anticoagulation options with a healthcare provider can help ensure better long-term treatment outcomes.

📢 Stay updated with the latest dialysis and kidney health insights – subscribe to our blog today!


🔍 Quick Summary: Apixaban for Hemodialysis Patients

📌 Reduces thrombosis risk by 52% in hemodialysis vascular access
📌 Maintains better vascular access patency than standard treatment
📌 Lower risk of major bleeding compared to warfarin
📌 Requires medical consultation before use


Healthy exercise methods for Health